Peptides for Weight Loss: What the 2026 Trial Data Says

The conversation about peptides for weight loss runs ahead of the evidence almost everywhere except the trial registry. As of April 2026, four peptide medications are approved by the FDA for chronic weight management, one of them is approved in Norway through DMP, and a fifth molecule has produced the largest mean weight-loss percentage ever published in a Phase 2 obesity trial without yet being approved anywhere. Reading peptides for weight loss honestly means reading those numbers in order.

Only four peptide medications are FDA-approved for weight loss as of 2026#

The regulatory perimeter is the most useful starting point, because almost everything sold under the "peptides for weight loss" banner sits outside it. As of April 2026, the FDA has granted approval to four peptide-based medications for chronic weight management: Wegovy injection (semaglutide 2.4 mg weekly), the higher-dose oral semaglutide tablet approved in late 2025 under the national priority voucher program, Zepbound (tirzepatide) approved in November 2023, and Saxenda (liraglutide 3 mg daily). Each of these is a peptide, each carries a defined approved indication, and each has a published label.

These FDA approved weight loss peptides share a structural feature: every one of them activates the GLP-1 receptor. The differences sit in what else they do. Liraglutide is a daily GLP-1 agonist with a relatively short half-life. Semaglutide is a weekly GLP-1 agonist with a long half-life. Tirzepatide is a weekly dual agonist that also activates the GIP receptor. The oral semaglutide tablet is a once-daily formulation that uses the absorption enhancer SNAC to allow systemic uptake of the peptide.

Outside that perimeter, nothing else is approved. AOD-9604, MOTS-c, tesofensine, fragment 176-191, and the various "research peptide" GLP-1 analogs distributed online occupy a different category, with a different evidence base and a different risk profile. The GLP-1 class explainer covers the receptor pharmacology; this guide covers the trial data, the side-effect profile, and the regulatory and grey-market boundary lines.

GLP-1 receptor activity drives the largest weight-loss effects on record#

Mechanistically, the reason peptide medications produce double-digit weight-loss percentages where prior pharmacotherapy struggled to clear 5% comes down to the receptors they engage. GLP-1, GIP, and glucagon are gut and pancreatic peptide hormones that, in their native forms, are released in response to nutrient intake. They have been shown in studies to slow gastric emptying, raise insulin sensitivity, dampen appetite signalling in the hypothalamus, and modulate energy expenditure.

A GLP-1 agonist binds the same GLP-1 receptor that the native hormone binds, but with a half-life measured in days rather than minutes. The result is a near-constant tonic signal across the appetite, glucose-control, and gastric-motility axes. Research suggests the appetite component is the dominant driver of weight loss at clinically used doses: most participants report eating smaller portions, getting full sooner, and finding food less interesting.

A dual GIP and GLP-1 agonist adds a second axis. GIP signalling has been shown to potentiate insulin secretion and act on adipose tissue. The clinical translation, evident in tirzepatide trials, is roughly a 50% larger mean weight-loss effect than semaglutide at the highest approved doses. A triple agonist that adds glucagon-receptor activity, like retatrutide, layers on lipolysis and resting energy expenditure. Each receptor added to the molecule corresponds to a larger mean weight-loss effect in cross-trial data.

Trial data ranks tirzepatide above semaglutide above liraglutide for weight loss#

The published trial data on peptides for weight loss is unusually clean, because the pivotal trials were run as randomised double-blind studies against placebo with hard endpoints (percent body-weight change at fixed timepoints). The numbers are extractable in single sentences.

STEP 1 (Wilding et al., NEJM 2021, n=1,961) measured semaglutide 2.4 mg weekly against placebo in adults with overweight or obesity. At 68 weeks, the semaglutide arm lost a mean 14.9% of body weight versus 2.4% on placebo. Roughly 86% of participants lost at least 5%, and 50% lost at least 15%.

SURMOUNT-1 (Jastreboff et al., NEJM 2022, n=2,539) measured three doses of tirzepatide against placebo at 72 weeks. The 5 mg arm lost 16.0%, the 10 mg arm 21.4%, and the 15 mg arm 22.5%. Each dose was statistically separated from placebo and from each other lower dose.

The first head-to-head trial, SURMOUNT-5 (Aronne et al., NEJM 2025), randomised adults with obesity to tirzepatide (up to 15 mg weekly) or semaglutide (up to 2.4 mg weekly) at the highest approved doses for 72 weeks. Tirzepatide produced a mean 20.2% body-weight reduction versus semaglutide's 13.7%. The proportion achieving at least 25% weight loss was 31.6% on tirzepatide versus 16.1% on semaglutide. Klarovel's semaglutide versus tirzepatide head-to-head guide walks through the secondary endpoints in detail.

Liraglutide (Saxenda) trails the weekly compounds. The Saxenda label data reports a mean 8% body-weight reduction at 56 weeks at the 3 mg daily dose, alongside dropout rates that are higher than the weekly comparators. Liraglutide was first to market in this class but is now the lowest-effect option among the FDA-approved weight loss peptides.

Drug	Receptor class	Highest-studied dose	Mean weight loss	Timepoint	Trial
Liraglutide (Saxenda)	GLP-1	3 mg daily	~8%	56 wk	Saxenda label
Semaglutide (Wegovy)	GLP-1	2.4 mg weekly	14.9%	68 wk	STEP 1
Tirzepatide (Zepbound)	GIP + GLP-1	15 mg weekly	22.5%	72 wk	SURMOUNT-1
Retatrutide	GIP + GLP-1 + glucagon	12 mg weekly	24.2%	48 wk	Phase 2 (NCT04881760)

For semaglutide for weight loss specifically, the Klarovel semaglutide complete guide covers titration ladder, label, and adverse-event timing. The named-peptide deep dives on tirzepatide for weight loss and retatrutide cover the same axes for those compounds.

Retatrutide is the next milestone, but it is not yet approved#

Retatrutide is the first triple GIP, GLP-1, and glucagon receptor agonist to complete Phase 2 in obesity. The Phase 2 trial (Jastreboff et al., NEJM 2023, NCT04881760, n=338) reported a mean 24.2% body-weight reduction at 48 weeks at the 12 mg weekly dose, versus 2.1% on placebo. At the time of publication, this was the largest mean weight-loss percentage documented for any pharmacotherapy in a general obesity population.

The Phase 3 program (the TRIUMPH and TRANSCEND trials) is ongoing, with the first Phase 3 readout (TRIUMPH-4) reporting in December 2025. As of April 2026, retatrutide is not approved by the FDA, the European Medicines Agency, or DMP in Norway. Eli Lilly has not yet filed a New Drug Application. Anyone reading "buy retatrutide" content should hold that fact next to the trial numbers, because the regulatory frame is the difference between a prescription medicine and a research-grade compound. Klarovel's research-positioning footing on these compounds is anchored on the disclosures page.

The retatrutide adverse-event profile in Phase 2 was class-typical for GLP-1-axis drugs, with one new signal: dysesthesia (altered skin sensation) appeared in roughly one in five participants at the 12 mg dose, a finding associated with glucagon-receptor activity that has no direct analog in approved GLP-1 medicines. Treatment discontinuation due to adverse events at 12 mg ran roughly four times the placebo rate. Preliminary evidence indicates the efficacy-tolerability tradeoff is real, and is the central question Phase 3 needs to resolve.

Two adjacent compounds in the same generation, cagrilintide (an amylin analog being co-formulated with semaglutide as CagriSema) and survodutide (a GLP-1 / glucagon dual agonist from Boehringer), are also in late-stage trials. Klarovel's deep dives on those compounds will follow as the data publishes.

Peptides for weight loss carry specific contraindications and a real side-effect profile#

Across the GLP-1-class trials, the adverse-event profile is overwhelmingly gastrointestinal and concentrated in the dose-escalation period. Pooled analyses and large self-reported datasets converge on a consistent picture: nausea is the most common event, followed by vomiting, constipation, diarrhoea, and fatigue. A 2026 Communications Medicine analysis of 410,198 self-reported posts from 67,008 users across r/Semaglutide and r/Tirzepatide reported nausea in roughly 37%, fatigue in 17%, vomiting in 16%, constipation in 15%, and diarrhoea in 13%. Users frequently describe the first month as the hardest, with most events fading by week 8, though clinical trial data shows a persistent minority who do not adapt.

The Wegovy 2025 label carries a Boxed Warning for medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN2), based on rodent thyroid C-cell tumour findings whose human relevance is unresolved. The label translates to a categorical contraindication for anyone with a personal or family history of MTC or MEN2. Acute pancreatitis, gallbladder disease, severe gastrointestinal disease, and worsening diabetic retinopathy in patients with type 2 diabetes are documented warnings.

Beyond weight loss, the SELECT trial (Lincoff et al., NEJM 2023, n=17,604) reported a 20% relative reduction in major adverse cardiovascular events with semaglutide 2.4 mg weekly over a mean 39.8 months of follow-up, in adults with overweight or obesity and pre-existing cardiovascular disease. Cardiovascular outcomes data is the input that has shifted GLP-1-class drugs from "weight loss" framing to "metabolic risk reduction" framing in the labels.

Compounded and grey-market peptides shift the risk profile#

The compounded GLP-1 market expanded dramatically during the 2022 to 2024 shortage period when compounding pharmacies were permitted to produce semaglutide and tirzepatide outside the FDA-approved supply chain. Once the FDA declared the shortages resolved, compounded versions of those molecules lost their legal pathway under section 503A of the Federal Food, Drug, and Cosmetic Act. Some operators continued under research-only framing.

A separate category of "research peptides" sits further outside the regulatory perimeter, and most of the "best peptides for fat loss" listicle pages traffic in this tier. AOD-9604, a 16-amino-acid fragment of human growth hormone marketed for fat loss, has produced minimal weight-loss effects in human trials, and the FDA declined to add AOD-9604 to its 503A bulks list in December 2024, removing the most plausible compounding pathway. MOTS-c, tesofensine, fragment 176-191, and similar compounds have early-stage data but no late-stage trials in obesity populations, and their availability runs through research-grade distributors rather than pharmacies. Compared to a GLP-1 weight loss peptide with a published Phase 3 dataset, this category is a different evidence base entirely.

Klarovel's editorial position on this category is that the science and the regulatory frame are different categories of question. The research-positioning disclosures page explains how Klarovel distributes research-grade peptides to vetted distributors for research purposes only, not as approved medicines, and how that framing differs from a prescription pathway. Anyone weighing a compounded or grey-market peptide for weight loss against an approved medication is choosing between two different evidence bases and two different oversight regimes.

A weight-loss peptide protocol is one input, not a standalone fix#

Every pivotal trial in this category combined the medication with structured lifestyle support: calorie-restricted diet (typically 500 kcal/day deficit), at least 150 minutes of moderate-intensity physical activity per week, and some form of behavioural counselling. The 14.9% in STEP 1 and the 22.5% in SURMOUNT-1 are not "drug-only" numbers. They are "drug plus lifestyle" numbers, in carefully recruited trial populations.

Real-world data has begun to land. Adherence in the field tends to be lower than in trials, side-effect-driven discontinuation rates higher, and the maintenance question is unresolved at the population level. The reading that does the most for autonomy is: the medication moves the curve, the lifestyle protocol bends it, and stopping the medication moves it back unless the lifestyle protocol is in place.

Klarovel's view is that a peptide for weight loss decision starts with a structured health profile (current bloodwork, family history, contraindications, prior treatment response), not with a SKU. The Klarovel health questionnaire walks the contraindication screening, surfaces the maintenance question early, and lines up the bloodwork the protocol expects. For anyone already on a protocol, the peptide titration calculator maps the dose escalation that the trial protocols built in to keep the GI events tolerable.

Each weight-loss peptide and comparison, in depth#

This guide is the overview. Each compound and head-to-head below has its own deep dive covering mechanism, the trial data behind it, dosing structure, and where the Norwegian regulatory line falls.

• AOD-9604 peptide: the fat-metabolism fragment guide: AOD-9604 is a 16-amino-acid growth hormone fragment studied for fat metabolism.
• Cagrilintide Complete Guide: Amylin Analog for Weight Loss: Cagrilintide is the long-acting amylin analog behind CagriSema.
• GLP-1 class: semaglutide, tirzepatide, retatrutide compared: Semaglutide, tirzepatide, and retatrutide share a pharmacology family but each activates different metabolic receptors.
• GLP-1 Muscle Loss: What the Data Actually Shows in 2026: GLP-1 muscle loss is real but manageable.
• Retatrutide: What the triple-agonist trials actually show: Retatrutide is the first triple GIP-GLP-1-glucagon agonist.
• Semaglutide: the complete evidence-based guide: Semaglutide is the first widely adopted GLP-1 receptor agonist for obesity and type-2 diabetes.
• Weight-Loss Medication in Norway 2026: The Complete Map: Every approved obesity medicine in Norway in 2026, plus the research-only frontier.
• Tirzepatide: the complete evidence-based guide: Tirzepatide is the first dual GIP/GLP-1 receptor agonist.
• Wegovy in Norway: A Complete Guide to Semaglutide 2.4 mg: Wegovy dosing, side effects, pricing in Norway, and STEP/SELECT trial outcomes for semaglutide 2.4 mg.

Where the peptides for weight loss conversation is heading#

The next twelve months will reshape the peptides for weight loss landscape in three predictable ways. The full retatrutide Phase 3 readout will produce the first Phase 3 dataset for a triple agonist, with cardiovascular outcomes following a year or two later. Cagrilintide, survodutide, and oral GLP-1 formulations will move from late-stage trials to filing decisions. Real-world durability data will start to answer the maintenance question that STEP 4 raised in 2021 and that no trial has fully closed.

What does not change in that window is the base reading: GLP-1 receptor activity drives the largest mean weight-loss effects in the published literature; the FDA-approved options remain the best-evidenced; the side-effect profile is real and dose-dependent; the maintenance question is structural; and the regulatory perimeter separates approved medicine from research-grade compound. Any peptide for weight loss decision that holds those five facts at once is a defensible decision.

Anyone considering a peptide protocol for weight loss should start with a structured health profile and recent bloodwork, not with a product SKU. Start with the Klarovel questionnaire to see whether a peptide medication fits the profile at all, and which compound the evidence supports.